Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.57 |
| ▸ | FNTA | P49354 | 2/20 | 0.56 |
| ▸ | FNTB | P49356 | 2/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11409649 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL6443935 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL3089610 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL11409647 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL6743893 | 1.00 | ALDH1A1 (0.69) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL356536 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL356537 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL901115 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| SCHEMBL1532465 | 0.98 | ALDH1A1 (0.71) | ALDH1A1ALOX15TRPV1FNTAFNTB | |
| Propionic Acid SCHEMBL14763668 | 0.93 | ALDH1A1 (0.65) | ALDH1A1ALOX15TRPV1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| EP-1089731-A4 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| EP-1089731-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-1999066929-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | COYOTE PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | disclosed |
| EP-1089731-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-1999066929-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258041-A1 | TREATING OSTEOPENIA AND RELATED DISORDERS WITH GERANYLGERANYL ACETONE AND DERIVATIVES THEREOF | GGPS1, EBP, GGCT | ALDH1A1 1058/4885ALOX15 927/4885TRPV1 3045/4885 |
| US-20150258039-A1 | PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA | UGP2, TGM2, GGCT | ALDH1A1 3952/4885ALOX15 3021/4885TRPV1 4475/4885 |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | ALDH1A1 4552/4885ALOX15 441/4885TRPV1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.